Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: A potential drug for AIDS and cancer patients

Keyphrases

• Cancer Patients 100%
• Potential Drugs 100%
• Tellurium 100%
• AIDS Patients 100%
• Toxicity Study 100%
• Immunomodulatory Drugs (IMiDs) 100%
• Bone Marrow 66%
• Food Consumption 66%
• Necropsy 66%
• Clinical Chemistry 66%
• Thymus 33%
• Routine Laboratory 33%
• Kidney 33%
• Liver 33%
• Platelet Count 33%
• Sprague-Dawley Rats 33%
• Clinical Signs 33%
• Ammonium 33%
• Tellurate 33%
• Selenium 33%
• Fibrous Tissue 33%
• Leukocyte Count 33%
• Histopathological Changes 33%
• Retinopathy 33%
• Garlic 33%
• Laboratory Examination 33%
• Bony Tissue 33%
• Vitamin E Deficiency 33%
• Blue Discoloration 33%
• Hematological System 33%
• Paraphimosis 33%
• β-globulin 33%
• Hepatoxicity 33%
• Haematological Studies 33%
• Female Sprague-Dawley Rats 33%
• Hindlimb Paresis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Ammonium Trichloro(dioxyethylene O,o')tellurate 100%
• Immunomodulating Agent 100%
• Acquired Immune Deficiency Syndrome 100%
• Rat 100%
• Sprague Dawley Rat 50%
• Hepatotoxicity 50%
• Allium sativum 50%
• Beta Globulin 50%
• Alpha Tocopherol Deficiency 50%
• Retinopathy 50%
• Phimosis 50%
• Paresis 50%
• Ammonium 50%
• Selenium 50%

Veterinary Science and Veterinary Medicine

• Rat 100%
• Cancer 100%
• Acquired Immune Deficiency Syndrome 100%
• Necropsy 66%
• Paraphimosis 33%
• Beta Globulin 33%
• Hepatotoxicity 33%
• Clinical Signs 33%
• Platelet 33%
• Leukocyte Count 33%
• Vitamin E Deficiency 33%
• Hindlimb 33%
• Paresis 33%
• Alpha Tocopherol Deficiency 33%
• Selenium 33%